Cargando…

Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis

Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwendich, Elena, Salinas Tejedor, Laura, Schmitz, Gernot, Rickert, Markus, Steinmeyer, Jürgen, Rehart, Stefan, Tsiami, Styliani, Braun, Jürgen, Baraliakos, Xenofon, Reinders, Jörg, Neumann, Elena, Müller-Ladner, Ulf, Capellino, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140103/
https://www.ncbi.nlm.nih.gov/pubmed/35626646
http://dx.doi.org/10.3390/cells11101609
_version_ 1784715017218686976
author Schwendich, Elena
Salinas Tejedor, Laura
Schmitz, Gernot
Rickert, Markus
Steinmeyer, Jürgen
Rehart, Stefan
Tsiami, Styliani
Braun, Jürgen
Baraliakos, Xenofon
Reinders, Jörg
Neumann, Elena
Müller-Ladner, Ulf
Capellino, Silvia
author_facet Schwendich, Elena
Salinas Tejedor, Laura
Schmitz, Gernot
Rickert, Markus
Steinmeyer, Jürgen
Rehart, Stefan
Tsiami, Styliani
Braun, Jürgen
Baraliakos, Xenofon
Reinders, Jörg
Neumann, Elena
Müller-Ladner, Ulf
Capellino, Silvia
author_sort Schwendich, Elena
collection PubMed
description Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis.
format Online
Article
Text
id pubmed-9140103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91401032022-05-28 Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis Schwendich, Elena Salinas Tejedor, Laura Schmitz, Gernot Rickert, Markus Steinmeyer, Jürgen Rehart, Stefan Tsiami, Styliani Braun, Jürgen Baraliakos, Xenofon Reinders, Jörg Neumann, Elena Müller-Ladner, Ulf Capellino, Silvia Cells Article Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis. MDPI 2022-05-11 /pmc/articles/PMC9140103/ /pubmed/35626646 http://dx.doi.org/10.3390/cells11101609 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schwendich, Elena
Salinas Tejedor, Laura
Schmitz, Gernot
Rickert, Markus
Steinmeyer, Jürgen
Rehart, Stefan
Tsiami, Styliani
Braun, Jürgen
Baraliakos, Xenofon
Reinders, Jörg
Neumann, Elena
Müller-Ladner, Ulf
Capellino, Silvia
Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title_full Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title_fullStr Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title_full_unstemmed Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title_short Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
title_sort modulation of dopamine receptors on osteoblasts as a possible therapeutic strategy for inducing bone formation in arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140103/
https://www.ncbi.nlm.nih.gov/pubmed/35626646
http://dx.doi.org/10.3390/cells11101609
work_keys_str_mv AT schwendichelena modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT salinastejedorlaura modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT schmitzgernot modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT rickertmarkus modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT steinmeyerjurgen modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT rehartstefan modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT tsiamistyliani modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT braunjurgen modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT baraliakosxenofon modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT reindersjorg modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT neumannelena modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT mullerladnerulf modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis
AT capellinosilvia modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis